Live Breaking News & Updates on Ramed Has Developeda Novel Protein Oral Delivery Pod Technology Oramed Is Seeking To Transform The Treatment Of Diabetes Through Its Proprietary Lead Candidate

Gurugram (Haryana) [India], October 8 (ANI/PRNewswire): Premas Biotech, developer of technologies & bioprocesses for novel proteins, today announced that Oravax Medical Inc., a US-based company that Premas Biotech is a shareholder in, reported positive preliminary data from its Phase 1 trial in South Africa of an oral Covid-19 vaccine candidate. Preliminary Phase 1 trial results from the first cohort include: - Significant antibody response (2-6 fold over baseline) as measured by multiple markers of immune response to VLP vaccine antigens observed in the majority of the patients dosed - was observed in 75 per cent of the patients dosed - No safety issues were observed, including mild symptoms Oravax Medical is a clinical-stage vaccine company developing oral vaccines that combine Premas Biotech's D-Crypt Platform with Oramed Pharmaceuticals' POD technology. Oravax's oral Covid-19 vaccine candidate is designed using D-Crypt technology as a triple antigen VLP vaccine that ....

South Africa , United States , Ambar Mehrotra , Nadav Kidron , Prabuddha Kundu , Gurugram Haryana , Oramed Pharmaceuticals Inc , Mymd Pharmaceuticals , Company Contact , Oramed Pharmaceuticals , Oravax Medical Inc , Oramed Pharmaceuticals Nasdaq , Premas Biotech , D Crypt Platform , Oramed Pharmaceutical , Managing Director , Protein Oral Delivery , Gurugram Haryana India , Ctober 8 Ani Prnewswire Premas Biotech , Eveloper Of Technologies Amp Bioprocesses For Novel Proteins , Oday Announced That Oravax Medical Inc , A Us Based Company That Premas Biotech Isa Shareholder In , Eported Positive Preliminary Data From Its Phase 1 Trial In South Africa Of An Oral Covid 19 Vaccine Candidate Results The First Cohort Include Significant Antibody Response 2 6 Fold Over Baseline As Measured By Multiple Markers Immune To Vlp Antigens Observed Majority Patients Dosed Was 75 Per Cent No Safety Issues Were , Ncluding Mild Symptoms Oravax Medical Isa Clinical Stage Vaccine Company Developing Oral Vaccines That Combine Premas Biotech 39 Sd Crypt Platform With Oramed Pharmaceuticals Pod Technology 39s Covid 19 Candidate Is Designed Usingd Asa Triple Antigen Vlp Targets Three Major Surface Proteins Of The Sars Cov 2 Virus Spike , Embrane And Envelope This Should Allow The Oral Vaccine Candidate To Triggera Protective Response Not Only Against Prevalent Strains Of Sars Cov 2 Virus But Also Emerging Mutations Quot We 39 Re Very Encouraged By Initial Data , Hich Indicates That Our Platform Can Be Safely And Successfully Used To Orally Deliver Protein Based Vaccines ,